Treatment of histoplasmosis

Satish Mocherla, L. Joseph Wheat

Research output: Contribution to journalReview article

39 Citations (Scopus)

Abstract

Histoplasmosis is an endemic mycosis, which is most prevalent in the Ohio and Mississippi valleys of North America. The causative organism is a dimorphic fungus, Histoplasma capsulatum. Histoplasmosis can present as a self-limited disease or cause life-threatening diseases resulting in considerable morbidity and mortality. Treatment is appropriate in patients with diffuse acute pulmonary infection, chronic pulmonary infection, mediastinal granuloma causing obstruction of important structures, or disseminated infection. Other chronic forms of disease such as fibrosing mediastinitis and broncholithiasis are unresponsive to pharmacologic treatment. Options for therapy include amphotericin B or one of its lipid formulations, and ketoconazole, itraconazole, or fluconazole. Recently, newer antifungal agents have been evaluated in animals models of histoplasmosis. Of these, a new triazole, posaconazole (SCH56592) appears most promising. Generally, amphotericin B or one of the lipid formulations is recommended as initial treatment in patients with more extensive diseases, felt to be ill enough to require hospitalization, and itraconazole for those who have milder illness, or to complete treatment after patients respond to amphotericin B. The role of intravenous formulation of itraconazole for severe histoplasmosis is unknown because studies comparing it with amphotericin B have not been conducted.

Original languageEnglish (US)
Pages (from-to)141-148
Number of pages8
JournalSeminars in Respiratory Infections
Volume16
Issue number2
DOIs
StatePublished - Jan 1 2001
Externally publishedYes

Fingerprint

Histoplasmosis
Amphotericin B
Itraconazole
Infection
Histoplasma
Lipids
Therapeutics
Mississippi
Lung
Triazoles
Ketoconazole
Mycoses
Fluconazole
Antifungal Agents
North America
Granuloma
Hospitalization
Chronic Disease
Fungi
Animal Models

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Microbiology (medical)

Cite this

Treatment of histoplasmosis. / Mocherla, Satish; Wheat, L. Joseph.

In: Seminars in Respiratory Infections, Vol. 16, No. 2, 01.01.2001, p. 141-148.

Research output: Contribution to journalReview article

Mocherla, Satish ; Wheat, L. Joseph. / Treatment of histoplasmosis. In: Seminars in Respiratory Infections. 2001 ; Vol. 16, No. 2. pp. 141-148.
@article{0aa0b1fa3a334ab39ff595efb483a376,
title = "Treatment of histoplasmosis",
abstract = "Histoplasmosis is an endemic mycosis, which is most prevalent in the Ohio and Mississippi valleys of North America. The causative organism is a dimorphic fungus, Histoplasma capsulatum. Histoplasmosis can present as a self-limited disease or cause life-threatening diseases resulting in considerable morbidity and mortality. Treatment is appropriate in patients with diffuse acute pulmonary infection, chronic pulmonary infection, mediastinal granuloma causing obstruction of important structures, or disseminated infection. Other chronic forms of disease such as fibrosing mediastinitis and broncholithiasis are unresponsive to pharmacologic treatment. Options for therapy include amphotericin B or one of its lipid formulations, and ketoconazole, itraconazole, or fluconazole. Recently, newer antifungal agents have been evaluated in animals models of histoplasmosis. Of these, a new triazole, posaconazole (SCH56592) appears most promising. Generally, amphotericin B or one of the lipid formulations is recommended as initial treatment in patients with more extensive diseases, felt to be ill enough to require hospitalization, and itraconazole for those who have milder illness, or to complete treatment after patients respond to amphotericin B. The role of intravenous formulation of itraconazole for severe histoplasmosis is unknown because studies comparing it with amphotericin B have not been conducted.",
author = "Satish Mocherla and Wheat, {L. Joseph}",
year = "2001",
month = "1",
day = "1",
doi = "10.1053/srin.2001.24244",
language = "English (US)",
volume = "16",
pages = "141--148",
journal = "Seminars in Respiratory Infections",
issn = "0882-0546",
number = "2",

}

TY - JOUR

T1 - Treatment of histoplasmosis

AU - Mocherla, Satish

AU - Wheat, L. Joseph

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Histoplasmosis is an endemic mycosis, which is most prevalent in the Ohio and Mississippi valleys of North America. The causative organism is a dimorphic fungus, Histoplasma capsulatum. Histoplasmosis can present as a self-limited disease or cause life-threatening diseases resulting in considerable morbidity and mortality. Treatment is appropriate in patients with diffuse acute pulmonary infection, chronic pulmonary infection, mediastinal granuloma causing obstruction of important structures, or disseminated infection. Other chronic forms of disease such as fibrosing mediastinitis and broncholithiasis are unresponsive to pharmacologic treatment. Options for therapy include amphotericin B or one of its lipid formulations, and ketoconazole, itraconazole, or fluconazole. Recently, newer antifungal agents have been evaluated in animals models of histoplasmosis. Of these, a new triazole, posaconazole (SCH56592) appears most promising. Generally, amphotericin B or one of the lipid formulations is recommended as initial treatment in patients with more extensive diseases, felt to be ill enough to require hospitalization, and itraconazole for those who have milder illness, or to complete treatment after patients respond to amphotericin B. The role of intravenous formulation of itraconazole for severe histoplasmosis is unknown because studies comparing it with amphotericin B have not been conducted.

AB - Histoplasmosis is an endemic mycosis, which is most prevalent in the Ohio and Mississippi valleys of North America. The causative organism is a dimorphic fungus, Histoplasma capsulatum. Histoplasmosis can present as a self-limited disease or cause life-threatening diseases resulting in considerable morbidity and mortality. Treatment is appropriate in patients with diffuse acute pulmonary infection, chronic pulmonary infection, mediastinal granuloma causing obstruction of important structures, or disseminated infection. Other chronic forms of disease such as fibrosing mediastinitis and broncholithiasis are unresponsive to pharmacologic treatment. Options for therapy include amphotericin B or one of its lipid formulations, and ketoconazole, itraconazole, or fluconazole. Recently, newer antifungal agents have been evaluated in animals models of histoplasmosis. Of these, a new triazole, posaconazole (SCH56592) appears most promising. Generally, amphotericin B or one of the lipid formulations is recommended as initial treatment in patients with more extensive diseases, felt to be ill enough to require hospitalization, and itraconazole for those who have milder illness, or to complete treatment after patients respond to amphotericin B. The role of intravenous formulation of itraconazole for severe histoplasmosis is unknown because studies comparing it with amphotericin B have not been conducted.

UR - http://www.scopus.com/inward/record.url?scp=0034963581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034963581&partnerID=8YFLogxK

U2 - 10.1053/srin.2001.24244

DO - 10.1053/srin.2001.24244

M3 - Review article

C2 - 11521246

AN - SCOPUS:0034963581

VL - 16

SP - 141

EP - 148

JO - Seminars in Respiratory Infections

JF - Seminars in Respiratory Infections

SN - 0882-0546

IS - 2

ER -